|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts显示文摘BACKGROUND:An updated definition of early allograft dysfunction(EAD) was recently validated in a multicenter study of 300 deceased donor liver transplant recipients.This analysis did not differentiate between donation after brain death(DBD) and donation after cardiac death(DCD) allograft recipients.METHODS:We reviewed our prospectively entered database for all DBD(n=377) and DCD(n=38) liver transplantations between January 1,2006 and October 30,2011.The incidence of EAD as well as its ability to predict graft failure and survival was compared between DBD and DCD groups.RESULTS:EAD was a valid predictor of both graft and patient survival at six months in DBD allograft recipients,but in DCD allograft recipients there was no significant difference in the rate of graft failure in those with EAD(11.5%) compared with those without EAD(16.7%)(P=0.664) or in the rate of death in recipients with EAD(3.8%) compared with those without EAD(8.3%)(P=0.565).The graft failure rate in the first 6 months in those with international normalized ratio ≥1.6 on day 7 who received a DCD allograft was 37.5% compared with 6.7% for those with international normalized ratio <1.6 on day 7(P=0.022).CONCLUSIONS:The recently validated definition of EAD is a valid predictor of patient and graft survival in recipients of DBD allografts.On initial assessment,it does not appear to be a useful predictor of patient and graft survival in recipients of DCD allografts,however a study with a larger sample size of DCD allografts is needed to confirm these findings.The high ALT/AST levels in most recipients of DCD livers as well as the predisposition to biliary complications and early cholestasis make these parameters as poor predictors of graft failure.An alternative definition of EAD that gives greater weight to the INR on day 7 may be more relevant in this population. | Kris P Croome William Wall Douglas Quan Sai Vangala Vivian McAlister Paul Marotta Roberto Hernandez-Alejandro | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，4： | 15 |
| 2 | A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma显示文摘AIM:To compare the clinical outcome and pathologic features of non-alcoholic steatohepatitis(NASH) patients with hepatocellular carcinoma(HCC) and hepatitic C virus(HCV) patients with HCC(another group in which HCC is commonly seen) undergoing liver transplantation.METHODS:Patients transplanted for HCV and NASH at our institution from January 2000 to April 2011 were analyzed.All explanted liver histology and pre-transplant liver biopsies were examined by two specialist liver histopathologists.Patient demographics,disease free survival,explant liver characteristics and HCC features(tumour number,cumulative tumour size,vascular invasion and differentiation) were compared between HCV and NASH liver transplant recipients.RESULTS:A total of 102 patients with NASH and 283 patients with HCV were transplanted.The incidence of HCC in NASH transplant recipients was 16.7%(17/102).The incidence of HCC in HCV transplant recipients was 22.6%(64/283).Patients with NASH-HCC were statistically older than HCV-HCC patients(P < 0.001).A significantly higher proportion of HCV-HCC patients had vascular invasion(23.4% vs 6.4%,P = 0.002) and poorly differentiated HCC(4.7% vs 0%,P < 0.001) compared to the NASH-HCC group.A trend of poorer recurrence free survival at 5 years was seen in HCV-HCC patients compared to NASH-HCC who underwent a Liver transplantation(P = 0.11).CONCLUSION:Patients transplanted for NASH-HCC appear to have less aggressive tumour features compared to those with HCV-HCC,which likely in part accounts for their improved recurrence free survival. | Roberto Hernandez-Alejandro Kris P Croome Martin Drage Nathalie Sela Jeremy Parfitt Natasha Chandok Paul Marotta Cheryl Dale William Wall Douglas Quan | 2012 | World Journal of Gastroenterology2012，18，31： | 5 |
| 3 | Perioperative neurological complications after liver transplantation are best predicted by pre-transplant hepatic encephalopathy显示文摘 | Dhar R Young GB Marotta P | 2008 | Neurocrit Care2008，8，2： | 1 |
| 4 | Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related li ver transplantation, a pilot study 显示文摘 | Willems B Ede M Marotta P | 2002 | J Hepatol2002，36，1： | 1 |
| 5 | Small dense low- density lipoprotein in familial combined hyperlipidemia: in- dependent of metabolic syndrome and related to history of cardiovascular events 显示文摘 | Pauciullo P Gentile M Marotta G | 2009 | Atberosclerosis2009，203，1： | 1 |
| 6 | Long-term outcomes of emergency liver transplantation for acute liver failure显示文摘 | CHAN G TAQI A MAROTTA P | | 0，，12： | 1 |
| 7 | Role of interferon alphaadministration after 2 deoxy eoformycin in the treatment of hairy cell leukemia patients显示文摘 | Marotta G Frassoldati A Zinzani P | 2006 | Eur J Haematol2006，77，2： | 1 |
| 8 | Efficacy and safety of rosuvastatin in the management of dyslipidemia显示文摘 | Rubba P Marotta G Gentile M | 2009 | Vasc Health Risk Manag2009，5，1： | 1 |
| 9 | Liver transplantation for incidental cholangioearcinoma : analysis of the Canadian experience 显示文摘 | Ghali P Marotta PJ Yoshida EM | 2005 | Liver Transpl2005，11，11： | 1 |
| 10 | Tolvaptan,an oral vasupressin antagonist,in the treatment of hyponatremia in cirrhosis显示文摘 | Cárdenas A Ginès P Marotta P | | 0，，03： | 1 |
| 11 | Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms显示文摘 | Zauber N P Sabbath-Solitare M Marotta S | 2005 | Cancer2005，104，4： | 1 |
| 12 | Efficacy and safety of rosuvastatin in the management of dyslipidemia 显示文摘 | Rubba P Marotta G Gentile M | 2009 | Vascular Health and Risk Mange-ment2009，5，1： | 1 |
| 13 | Inadverten foreign body embolization in diagnostic and therapeutic cerebral angiography显示文摘 | Shannon P Billbao JM Marotta T | 2006 | AJNR2006，27，2： | 1 |
| 14 | The interacting effect of cognitive and motor task demands on performance of gait, balance and cognition in young adults 显示文摘 | Szturm T Maharjan P Marotta JJ | 2013 | Gait Posture2013，38，4： | 1 |
| 15 | Efficacy and safety of rosuvastatin in the management of dyslipidemia 显示文摘 | RUBBA P MAROTTA G GENTILE M | 2009 | Vasc Health Risk Manage2009，5，： | 1 |
| 16 | Tolvaptan, anoral vasopressin antagonist,in the treatment of hyponatremiain cirrhosis 显示文摘 | CARDENAS A GINES P MAROTTA P | 2012 | J Hepatol2012，56，3： | 1 |
| 17 | Role of interferon alpha administration after 2-deoxycoformycin in the treatment of hairycell leukemia patients显示文摘 | Marotta G Frassoldati A Zinzani P | 2006 | Eur J Haematol2006，77，2： | 1 |
| 18 | Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients 显示文摘 | Bain VG Kaita KD Marotta P | 2008 | Clin Gastroenterol Hepatol2008，6，6： | 1 |
| 19 | Inadvertent foreign body embolization in diagnostic and therapeutic cerebral angiography 显示文摘 | Shannon P Billbao JM Marotta T | 2006 | Am J Neuroradiol2006，27，2： | 1 |
| 20 | Prospective evaluation of the role of quantitative Doppler ultrasound surveillance in liver transplantation显示文摘 | Stell D Downey D Marotta P | 2004 | Liver Transpl2004，10，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员